UPDATE 1-Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

2

* Lilly ups full-year revenue forecast to as much as $92 billion * Weight-loss drugs Mounjaro, Zepbound drive Q3 earnings beat * Medicare pricing fears could ease as Lilly captures new patients (Adds

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)